FBXO45: A promising drug target and biomarker for the treatment of cancer

Target Name: FBXO45

NCBI ID: G200933

FBXO45

FBXO45: A promising drug target and biomarker for the treatment of cancer

FBXO45 is a protein that is expressed in various tissues of the body, including the brain, heart, liver, and blood vessels. It is a member of the F-box only protein (FBX) family, which are known for their unique structure and function. One of the interesting features of FBXO45 is its potential as a drug target or biomarker for the treatment of cancer. In this article, we will explore the biology and potential therapeutic applications of FBXO45.

Structure and function

FBXO45 is a 21 kDa protein that contains a unique F-box domain. This domain is known for its ability to interact with various molecules, including small molecules, peptides, and even proteins. The F-box domain is responsible for the protein's unique structure and function.

One of the most significant features of FBXO45 is its ability to form a binary complex with small molecules, such as drug molecules or radioactive isotopes. This ability allows the protein to interact with and stabilize these molecules, which can lead to increased levels of the drug or radioactive isotope in the cells.

FBXO45 is also known for its role in the regulation of cellular processes, including cell growth, apoptosis, and angiogenesis. It is expressed in various tissues of the body and is involved in the development and maintenance of tissues, including blood vessels, neurons, and tissues.

Potential therapeutic applications

FBXO45 has the potential as a drug target or biomarker for the treatment of various types of cancer, including breast, lung, and ovarian cancer. One of the reasons for its potential as a drug target is its ability to interact with small molecules and regulate cellular processes, which can lead to the inhibition of cancer cell growth and the inhibition of angiogenesis.

FBXO45 has also been shown to play a role in the regulation of apoptosis, which is the process by which cells die. Studies have shown that FBXO45 can induce apoptosis in cancer cells, which can lead to the inhibition of cancer cell growth and the inhibition of angiogenesis.

Another potential therapeutic application of FBXO45 is its ability to target cancer cells in the bone marrow. Cancer cells can often invade the bone marrow and cause the development of a new cancerous lesion. FBXO45 has been shown to be able to inhibit the invasiveness of cancer cells in the bone marrow, which can lead to the inhibition of cancer cell growth and the inhibition of angiogenesis.

FBXO45 has also been shown to be involved in the regulation of cellular processes that are important for cancer cell growth and angiogenesis. For example, studies have shown that FBXO45 can inhibit the angiogenesis of cancer cells, which can lead to the inhibition of cancer cell growth.

Conclusion

FBXO45 is a protein that has the potential as a drug target or biomarker for the treatment of cancer. Its unique structure and function, as well as its ability to interact with small molecules and regulate cellular processes, make it an attractive candidate for cancer treatment. Further research is needed to fully understand the biology and potential therapeutic applications of FBXO45.

Protein Name: F-box Protein 45

Functions: Component of E3 ubiquitin ligase complex consisting of FBXO45, MYCBP2 and SKP1 (PubMed:29997255). Functions in substrate recognition but plays also an important role in assembly of the complex (PubMed:29997255). Required for normal neuromuscular synaptogenesis, axon pathfinding and neuronal migration (By similarity). Regulates neuron migration during brain development through interaction with N-cadherin/CDH2 after secretion via a non-classical mechanism (By similarity). Plays a role in the regulation of neurotransmission at mature neurons (By similarity). May control synaptic activity by controlling UNC13A via ubiquitin dependent pathway (By similarity). Specifically recognizes TP73, promoting its ubiquitination and degradation. Polyubiquitinates NMNAT2, an adenylyltransferase that acts as an axon maintenance factor, and regulates its stability and degradation by the proteasome (PubMed:29997255). Acts also by ubiquitinating FBXW7 during prolonged mitotic arrest and promotes FBXW7 proteasomal degradation (PubMed:31285543). Induces subsequently an increase in mitotic slippage and prevents mitotic cell death (PubMed:31285543). In response to influenza infection, mediates interferon-lambda receptor IFNLR1 polyubiquitination and degradation through the ubiquitin-proteasome system by docking with its intracellular receptor domain (PubMed:36379255)

The "FBXO45 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FBXO45 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets